+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention

The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention

Chinese Clinical Oncology 2(1): 7

Almost one fifth of malignancies worldwide and about one quarter in China are associated with viral or bacterial infections, mediating an inflammatory environment in the tumor. Hepatitis viruses (B and C), Epstein Barr Virus (EBV), and helicobacter pylori have been linked to liver, gastric, and nasopharyngeal cancer. The context of infection and chronic inflammation in these cancers may provide an opportunity for therapeutic intervention based on the role of immune checkpoint pathways, which are an important defense mechanism of many cancers against a tumor-directed immune response. Specifically, the expression of the inhibitory receptor PD-1 on the surface of activated T cells has been associated with T cell exhaustion in inflammatory and tumor environments. Furthermore, tumors have been found to over-express the PD-1 ligand B7-H1. Recent therapeutic successes with monoclonal antibodies directed against both B7-H1 and PD-1 in patients with advanced melanoma, renal cell cancer (RCC), and non-small cell cancer, along with the prominent role of this immune checkpoint axis in the inflammatory tumor context, suggest that B7-H1/PD-1 blockade may be particularly beneficial in cancers associated with infections and inflammation.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 036902541

Download citation: RISBibTeXText

PMID: 25841448

Related references

Professor Frank McCormick: K-Ras proteins offer new opportunities for therapeutic intervention against human cancers. Annals of Translational Medicine 2(12): 126-126, 2015

Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. International Reviews of Immunology 27(5): 375-387, 2008

Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. Critical Reviews in Immunology 35(6): 505-527, 2015

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Communication and Signaling 9: 13, 2011

Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development. Microbiology and Molecular Biology Reviews 81(2), 2017

Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochemical Pharmacology 92(1): 12-21, 2015

The Hippo signaling pathway and translational opportunities for brain cancers. Cns Oncology 1(2): 113-115, 2015

Opportunities for pharmacological intervention in the ras pathway. Annals of Oncology 6 Suppl 1: 63-67, 1995

The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma. Cellular Signalling 28(10): 1555-1562, 2017

Cytokines Opportunities for therapeutic intervention. Gaginella, T S , Guglietta, A Drug development: Molecular targets for GI diseases 61-87, 2000

Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Frontiers in Psychiatry 10: 103, 2019

B cells and beyond: therapeutic opportunities targeting inflammation. Inflammation and Allergy Drug Targets 6(3): 142-149, 2007

Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. Cell Cycle 12(17): 2705-2706, 2014

Opportunities for Therapeutic Intervention During Machine Perfusion. Current Transplantation Reports 4(2): 141-148, 2017

TRP channels in neurogastroenterology: opportunities for therapeutic intervention. British Journal of Pharmacology 162(1): 18-37, 2011